Radioimmunotherapy with α-particle emitting radioimmunoconjugates

Acta Oncologica

Volumn 35, Issue 3, 1996, Pages 373-379

  Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH; MONOCLONAL ANTIBODY;

ALPHA RADIATION; ANTIBODY LABELING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CONFERENCE PAPER; HUMAN; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030013280     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609101654     Document Type: Conference Paper

References (36)

1. Bast RC Jr, Zalutsky MR, Frankel A. Monoclonal serotherapy. In: Holland JF, ed. Cancer Medicine, 3rd edition. Lea and Febiger, 1993: 968-82.
2. 224Ra. Appl Radiat Isot 1988; 39: 282-6.
3. Turkington TG, Zalutsky MR, Jaszczak RJ, Garg P, Vaidyanathan G, Coleman RE. Measuring astatine-211 distributions with SPECT. Phys Med Biol 1993; 38: 1121-30.
4. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol 1995; 22: 45-54.
5. Zalutsky MR, Narula AS. Astatination of proteins using an N-succinimidyl tri-n-butylstannylbenzoate intermediate. Appl Radiat Isot 1988; 39: 227-32.
6. 2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA 1989; 86: 7149-53.
7. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 1490-7.
8. Humm JL. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 1987; 13: 1767-73.
9. Roeske JC, Chen GTY. A dosimetry model for intracavitary radioimmunotherapy of cystic brain tumors. Antibody Immunoconjugates Radiopharm 1991; 4: 637-47.
10. Roeske JC, Chen GTY, Atcher RW, et al. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys 1990; 19: 1539-48.
11. Hall EJ. Radiobiology for the Radiologist. 3rd edition. Philadelphia: Lippincott, 1988: 161-77.
12. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother 1988; 29: 631-58.
13. Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldman TA. Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 1986; 83: 474-8.
14. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80: 449-52.
15. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988; 240: 1024-6.
16. Macklis RM, Kaplan WD, Ferrara JLM, et al. Resident's essay award: alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys 1989; 16: 1377-87.
17. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992; 130: 220-6.
18. Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990; 50: 4221-6.
19. 212Bi) therapy. Cancer Res 1993; 53: 5683-9.
20. Huneke RB, Pippin CG, Squire RA, Brechbiel MW, Gansow OA, Strand M. Effective α-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res 1992; 52: 5818-20.
21. 2-. Radiochim Acta 1993; 60: 1-10.
22. Aaij C, Tschroots WRJM, Lindner L, Feltkamp TEW. The preparation of astatine labelled proteins. Int J Appl Radiat Isot 1975; 26: 25-30.
23. Vaughan ATM, Fremlin JH. The preparation of astatine labelled proteins using an electrophilic reaction. Int J Nucl Med Biol 1978; 5: 229-30.
24. Friedman AM, Zalutsky MR, Wung W, et al. Preparation of a biologically stable and immunogenically competent astatinated protein. Int J Nucl Med Biol 1977; 4: 219-24.
25. Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Radiat Isot 1987; 38: 1051-5.
26. Narula AS, Zalutsky MR. No-carrier-added astatination of N-succinimidyl-3-(tri-n-butylstannyl)benzoate (ATE) via electrophilic destannylation. Radiochimica Acta 1989; 47: 131-5.
27. 211At-labelled Concanavalin A bound to cell membranes. J Radioanal Chem 1981; 64: 33-9.
28. 211At labelled lectins and antibodies-I. Int J Nucl Med Biol 1982; 9: 167-71.
29. 211-labeled bovine serum albumin, free astatine-211 and external-beam x rays. Radiat Res 1994; 139: 178-84.
30. 211At-labelled monoclonal antibody. Br J Cancer 1994; 69: 1000-5.
31. 125I-labelled monoclonal antibodies. Biodistribution in mice carrying human osteosarcoma xenografts. J Labelled Cmpd Radiopharm 1994; 34: 773-85.
32. 125I]iodobenzoyl conjugate. Bioconjugate Chem 1991; 2: 171-9.
33. 2. Nucl Med Biol 1993; 20: 917-27.
34. 2 fragment. Cancer Res 1990; 50: 3514-20.
35. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 1994; 54: 4719-25.
36. Zalutsky MR, Schuster JM, Garg PK, Archer Jr GE, Dewhirst MW, Bigner DD. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. Recent Results Cancer Res 1996; 141: 101-21.